The scientist’s investigation covers issues in Immunology, Immunotherapy, Cytotoxic T cell, Antigen and Epstein–Barr virus. The study incorporates disciplines such as Hematopoietic stem cell transplantation, Transplantation and Virology in addition to Immunology. His Immunotherapy study is related to the wider topic of Immune system.
His Cytotoxic T cell research is multidisciplinary, incorporating elements of T cell, Cancer research and T lymphocyte. Cliona M. Rooney interconnects Tumor microenvironment, Molecular biology and Chimeric antigen receptor in the investigation of issues within Antigen. Cliona M. Rooney has included themes like Herpesviridae and Lymphoma in his Epstein–Barr virus study.
Cliona M. Rooney spends much of his time researching Immunology, Cytotoxic T cell, Antigen, Immunotherapy and T cell. His research links Virology with Immunology. His Cytotoxic T cell study combines topics in areas such as Molecular biology and Transplantation.
His studies in Antigen integrate themes in fields like Cancer research and Chimeric antigen receptor. In his work, Hematopoietic stem cell and Lymphoproliferative disorders is strongly intertwined with Hematopoietic stem cell transplantation, which is a subfield of Immunotherapy. Cliona M. Rooney combines subjects such as Human leukocyte antigen and Cell biology with his study of T cell.
Cliona M. Rooney focuses on Immunology, Antigen, T cell, Cancer research and Immunotherapy. The various areas that Cliona M. Rooney examines in his Immunology study include Cytotoxic T cell and Hematopoietic stem cell transplantation, Transplantation. Cliona M. Rooney has researched Antigen in several fields, including Tumor microenvironment, Immune system and Chimeric antigen receptor.
His T cell study combines topics from a wide range of disciplines, such as Molecular biology, Viral vector, In vivo and Virology. His research in Cancer research intersects with topics in Car t cells, B cell and CD19. His work carried out in the field of Immunotherapy brings together such families of science as Receptor and Cytokine.
His primary scientific interests are in Immunology, Antigen, Chimeric antigen receptor, Immunotherapy and T cell. His biological study spans a wide range of topics, including Cytotoxic T cell, Transplantation and Virology. He is interested in Antigen-presenting cell, which is a branch of Cytotoxic T cell.
Cliona M. Rooney has researched Antigen in several fields, including Tumor microenvironment, Immune system, Receptor and Cancer research. His research in Immunotherapy intersects with topics in Cell culture, K562 cells, Lymphoma, Interleukin and In vivo. His studies deal with areas such as Inhibitory postsynaptic potential, Viral vector, Long terminal repeat and Cell biology as well as T cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
C.M Rooney;C.Y.C Ng;S Loftin;C.A Smith.
The Lancet (1995)
Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients
Cliona M. Rooney;Colton A. Smith;Colton A. Smith;Catherine Y.C. Ng;Catherine Y.C. Ng;Susan K. Loftin;Susan K. Loftin.
Inducible apoptosis as a safety switch for adoptive cell therapy
Antonio Di Stasi;Siok Keen Tey;Gianpietro Dotti;Yuriko Fujita.
The New England Journal of Medicine (2011)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule;Barbara Savoldo;G. Doug Myers;G. Doug Myers;Claudia Rossig.
Nature Medicine (2008)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
Barbara Savoldo;Carlos Almeida Ramos;Carlos Almeida Ramos;Enli Liu;Martha P. Mims.
Journal of Clinical Investigation (2011)
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Chrystal U. Louis;Chrystal U. Louis;Barbara Savoldo;Barbara Savoldo;Gianpietro Dotti;Gianpietro Dotti;Martin Pule.
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
Helen E. Heslop;Catherine Y.C. Ng;Congfen Li;Colton A. Smith.
Nature Medicine (1996)
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Helen E. Heslop;Karen S. Slobod;Martin A. Pule;Gregory A. Hale.
Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed;Vita S. Brawley;Meenakshi Hegde;Catherine Robertson.
Journal of Clinical Oncology (2015)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo;Tony Reid;Leyo Ruo;Caroline J. Breitbach.
Nature Medicine (2013)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: